Clinical Trial Update: Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating anlotinib combined with icotinib as first-line therapy for patients with EGFR-mutant non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• icotinib (icotinib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: UNKNOWN